Skip to main content
. 2022 Jan 28;4(1):e210070. doi: 10.1148/rycan.210070

Figure 4:

Initial preclinical PET studies of 18F fluorthanatrace (18F-FTT) demonstrate the ability of the radiotracer to measure occupancy of a poly (adenosine diphosphate–ribose) polymerase inhibitor (PARPi). MDA-MB-231 tumor–bearing female athymic nude mice (n = 25) were injected with 18F-FTT (11.4 MBq ± 0.5), showing baseline tumor uptake (indicated by the circle showing the position of the tumor). The tracer uptake was blocked by the administration of olaparib (n = 14), a known PARPi, but not by iniparib (n = 11), as shown on the images (left panel) and the quantitative measurement as presented as percentage of injected dose per milliliter (right panel). Iniparib has no inhibitory effect on PARP-1 activity.

Initial preclinical PET studies of 18F fluorthanatrace (18F-FTT) demonstrate the ability of the radiotracer to measure occupancy of a poly (adenosine diphosphate–ribose) polymerase inhibitor (PARPi). MDA-MB-231 tumor–bearing female athymic nude mice (n = 25) were injected with 18F-FTT (11.4 MBq ± 0.5), showing baseline tumor uptake (indicated by the circle showing the position of the tumor). The tracer uptake was blocked by the administration of olaparib (n = 14), a known PARPi, but not by iniparib (n = 11), as shown on the images (left panel) and the quantitative measurement as presented as percentage of injected dose per milliliter (right panel). Iniparib has no inhibitory effect on PARP-1 activity.